Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Outline of Final Research Achievements |
Gain of function mutations of fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3 cause craniosynostosis such as Apert, Crouzon, Pfeiffer, Muenke syndromes and Thanatophoric dysplasia. Further, Apert syndrome and Crouzon syndrome show limb defects. The mice, in which Runx2 was overexpressed in carvaria and limbs, showed craniosynostosis and limb defects. In the mice, FGF expression in limbs was abnormal, indicating that Runx2 is involved in the regulation of FGF signaling.
|